Non-muscle-invasive Bladder Cancer

Covid-19 EAU NMIBC Recommendations

Papillary urothelial neoplasm of low malignant potential

Urol Oncol 2020: 29; 440-448

EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

Annals of Oncol 2019: 0; 1–31

Grading of Urothelial Carcinoma and The New “World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016”

Eur Urol Focus 2019: 5; 457-466

European Association of Urology Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update

Eur Urol 2019: 76; 639-657.

Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer A Critical Assessment from the European Association

Eur Urol Focus. 2018 S2405

Indication for a Single Postoperative Instillation of Chemotherapy in Non–muscle-invasive Bladder Cancer: What Factors Should Be Considered?

Eur Urol Focus 2018: 4; 525-528

Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non–muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review

Eur Urol 2017: 72; 801-813

EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder Update 2016

Eur Urol 2017: 71; 447-461

Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa–pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?

Eur Urol 2016: 69; 231-244